Sensei Biotherapeutics (NASDAQ:FTH) CFO Acquires $117,500.00 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson acquired 5,000 shares of Sensei Biotherapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was acquired at an average cost of $23.50 per share, with a total value of $117,500.00. Following the purchase, the chief financial officer owned 46,688 shares in the company, valued at $1,097,168. The trade was a 11.99% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Sensei Biotherapeutics Stock Performance

FTH traded down $1.34 on Wednesday, hitting $23.66. The company had a trading volume of 114,325 shares, compared to its average volume of 89,623. The firm has a market cap of $31.70 million, a P/E ratio of -0.17 and a beta of -0.26. Sensei Biotherapeutics, Inc. has a 1-year low of $6.32 and a 1-year high of $36.76.

Analysts Set New Price Targets

Several analysts recently weighed in on FTH shares. HC Wainwright began coverage on Sensei Biotherapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $60.00 target price for the company. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Robert W. Baird started coverage on shares of Sensei Biotherapeutics in a research report on Friday, June 26th. They set an “outperform” rating and a $57.00 target price on the stock. Finally, Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $58.50.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.